Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis-Reference-Cited by-同舟云学术

Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis

Published:2019-02-12 Issue:5 Volume:94 Page:26-32
ISSN:2313-6294
Container-title:Vestnik dermatologii i venerologii
language:
Short-container-title:Vestnik dermatologii i venerologii

Author:

Bakulev A. L.¹

Affiliation:

1. Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of the Russian Federation

Publisher

Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov

Reference41 articles.

1. Langley R. G. Exploring new concepts in the successful management of psoriasis. J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:1-2.

2. Kubanova A. A., Kubanov A. A., Znamenskaj L. F., Chikin V. V., Bakulev A. L., Khobeych M. M. et al. Psoriasis. In: Federal clinical guidelines. Dermatovenerology, 2015: Diseases of the skin.Sexually transmitted infections. 5th ed., revised and enlarged. Moscow: Delovoyexpress, 2016. P. 415-470. (In Russ.)

3. Bovenschen H. J., Vande Kerkhof P. C., Van Erp P. E. et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. Journal of Investigative Dermatology. 2011;131:1853-1860. u

4. Nestle F., Kaplan D. H., Barcer J. Psoriasis. N Engl J Med. 2009;361:496-509.

5. Korn T., Bettelli E., Oukka M., Kuchroo V. K. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology of psoriasis in the Russian Federation according to the patient registry;Vestnik dermatologii i venerologii;2022-01-15

2. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext;Vestnik dermatologii i venerologii;2019-10-02